Cipla in deal with Teva for South African marketing
Indian drugmaker Cipla (BSE: 500087) saw its share rise 2.6% to 600.65 rupees, as the company revealed it has entered into a collaboration with Israel's Teva Pharmaceuticals Industries (NYSE: TEVA), the world’s largest generic drugmaker, for sales and distribution of the latter's drugs in South Africa.
The collaboration will focus on oncology, central nervous system, women's health, cardiovascular, ophthalmology and other speciality products.
The agreement is between Medpro Pharmaceuticals, a subsidiary of Cipla Medpro and Teva Pharmaceuticals Pty, the company said in a filing to the Bombay Stock Exchange. "The collaboration is a sales and distribution agreement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa," the company said.
Cipla Medpro chief executive Paul Miller said: "This collaboration is highly complementary and aligns strongly with our philosophy of providing South Africans access to a broader range of affordable medicines."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze